Saszynski J.S., McManus D., Zhou Z., et al. Trends in atrial fibrillation complicating acute myocardial infarction. Am. J. Cardiol. 2009;104(2):169-174.
Schmitt J., Duray G., Gersh B. et al. Atrial fibrillation in acute myocardial infarction: A systematic review of the incidence, clinical features and prognostic implications. Eur Heart J. 2009;30:1038-45.
ACTIVE Writing Group of the ACTIVE Investigators, Connolly S., Pogue J., Hart R., Pfeffer M., Hohnloser S., Chrolavicius S., Pfeffer M., Hohnloser S., Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet. 2006 Jun 10;367(9526):1903-12;
Hansen M.L., Sørensen R., Clausen M.T., FogPetersen M.L., Raunsø J., Gadsbøll N., Gislason G.H., Folke F., Andersen S.S., Schramm T.K., Abildstrøm S.Z., Poulsen H.E., Køber L., TorpPedersen C. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010 Sep 13;170(16):1433-41.
Sørensen R., Hansen M.L., Abildstrom S.Z., et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374:1967–1974.
Dewilde W.J., Oirbans T., Verheugt F.W., Kelder J.C., De Smet B.J., Herrman J.P., Adriaenssens T., Vrolix M., Heestermans A.A., Vis M.M., Tijsen J.G., van ‘t Hof A.W., ten Berg J.M.; WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomized, controlled trial. Lancet. 2013 Mar 30;381(9872):1107-15.
Fiedler K.A., Maeng M., Mehilli J., SchulzSchüpke S., Byrne R.A., Sibbing D., Hoppmann P., Schneider S., Fusaro M., Ott I., Kristensen S.D., Ibrahim T., Massberg S., Schunkert H., Laugwitz K.L., Kastrati A., Sarafoff N. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. J Am Coll Cardiol. 2015 Apr 28;65(16):1619-1629.
Dans A.L., Connolly S.J., Wallentin L., Yang S., Nakamya J., Brueckmann M., et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013;127:634–640.
Alexander J.H., Lopes R.D., Thomas L., Alings M., Atar D., Aylward P., Goto S., Hanna M., Huber K., Husted S., Lewis B.S., McMurray J.J., Pais P., Pouleur H., Steg P.G., Verheugt F.W., Wojdyla D.M., Granger C.B., Wallentin L. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2014 Jan;35(4):224-32.
Gibson M., Mehran O., Bode C., Halperin J., et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016; 375:2423-2434.
Cannon C.P., Bhatt D.L., Oldgren J., Lip G.Y.H., et al, for the RE-DUAL PCI Steering committee and investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377:1513-1524.
Piccini J.P., Jones W.S. Triple Therapy for Atrial Fibrillation after PCI. N Engl J Med. 2017 Oct 19;377(16):1580-1582.
Piccini J.P., Jones W.S. Triple Therapy for Atrial Fibrillation after PCI. N Engl J Med. 2017 Oct 19;377(16):1580-1582.
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2017;0:1–48.
Steffel J., Verhamme P., Potpara T.S., Albaladejo P., Antz M., Desteghe L., Haeusler K.G., Oldgren J., Reinecke H., Roldan-Schilling V., et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 20184;39(16):1330-1393;
2018 ESC/EACTS Guidelines on myocardial revascularization The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2018;00:1–96.